Sentences with phrase «epidermal growth factor receptor»

The analysis also found that Asian / Pacific Islander women were more likely to be diagnosed with another subtype of breast cancer: so - called human epidermal growth factor receptor 2 (HER2)- overexpressing breast cancer.

Changes in cell junctions induced by inhibition of epidermal growth factor receptor in oral squamous cell carcinoma cells.

The advent of therapies directed at tumors with mutations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and B - Raf proto - oncogene (BRAF) genes over the past decade have dramatically changed outcomes, he says.

The Alabama scientists have now shown how it works against head and neck cancers: It blocks a protein called epidermal growth factor receptor, or EGFR.

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

Researchers found that a combination of drugs — one targeting epidermal growth factor receptor (EGFR) and one targeting tumor necrosis factor (TNF)-- effectively blocks the cancer from using TNF as an escape route.

The drug Gefitinib is used to treat breast, lung, and other cancers by inhibiting epidermal growth factor receptor (EGFR) signaling, but it has only a limited effect on prostate cancer.

Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6.

Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.

Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.

Neutrophil - to - Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor

«CRKII most likely regulates the stability of mutated epidermal growth factor receptors and drives cancer growth by promoting signaling, or communication, within cancer cells,» said Julia Petschnigg, lead author on the paper and a postdoctoral fellow at U of T. «We found that a combinatorial chemotherapy that inhibits those mutated receptors and CRKII could be beneficial in treating lung cancer.»

Recent findings suggest a novel positron emission tomography (PET) imaging approach determining epidermal growth factor receptor (EGFR) mutation status for improved lung cancer patient management.

Two studies are providing new insight into germline epidermal growth factor receptor (EGFR) T790M mutation in familial non-small cell lung cancer (NSCLC).

A major challenge for assessing driver mutations, such as epidermal growth factor receptor (EGFR) mutations, in advanced disease is the scarcity of suitable biopsy tissue for molecular testing.

For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells — specifically those testing positive for human epidermal growth factor receptor 2 (HER2).

Alice Shaw recalls a signal moment in 2004 — just as she was finishing her oncology fellowship at MIT — when scientists discovered that mutations in a gene for epidermal growth factor receptor (EGFR) were the culprits in about 10 to 15 percent of lung cancer patients.

Researchers at the San Diego Supercomputer Center (SDSC) and the Moores Cancer Center at the University of California, San Diego, have described for the first time the molecular mechanism of cancer development caused by well - known «resistance» mutations in the gene called epidermal growth factor receptor (EGFR).

In addition to RIPK2 binding as part of this computer - based (initial) screening, we selected compounds that inhibited epidermal growth factor receptor (IC50 values > 1000 nM; weak inhibitory activity) along with weak binding interactions in the EGFR and c - ABL binding sites, two common off - targets for previously identified RIPK2 inhibitors.

DENVER — Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations.

They infected a non-small cell lung cancer cell line containing an activating mutation in epidermal growth factor receptor (EGFR) with the ClonTracer library and monitored population dynamics after treatment with EGFR inhibitor, erlotinib.

Here, we report that capsaicin has a cocarcinogenic effect on 12 - O - tetradecanoylphorbol -13-acetate (TPA)-- promoted skin carcinogenesis in vivo and is mediated through the epidermal growth factor receptor (EGFR), but not the transient receptor potential vanilloid subfamily member 1 (TRPV1).

Between 10 and 30 percent of NSCLC cases are driven by mutations in the epidermal growth factor receptor (EGFR) gene.

Clinically important findings suggest that targeting the epidermal growth factor receptor (EGFR) and the fibroblast growth factor receptor (FGFR) cellular pathways may benefit thousands of patients with this disease, according to the study published today in the journal PLOS Genetics.

About 15 to 20 % of breast cancers are classified as «triple negative,» so called because these tumors do not express three key proteins that are biomarkers and / or drug targets for breast cancer: the estrogen receptor, the progesterone receptor, and HER2 (a member of the epidermal growth factor receptor family).

That protein, CRKII, interacts with another protein called an epidermal growth factor receptor.

The growth factors are human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 3 (HER3), and epidermal growth factor receptor (EGFR).

Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.

The study, called the PALOMA - 3, enrolled 521 pre - / peri - and postmenopausal patients with hormone receptor positive and human epidermal growth factor receptor - negative (HR + / HER2 --RRB- advanced disease.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have mutations in the EGFR gene.

Epidermal growth factor receptor (EGFR) mutations found in the circulating free tumor DNA (ctDNA) from the plasma of advanced non-small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient - matched tumor tissue DNA.

Human epidermal growth factor receptor 2 (HER2) is upregulated in a subset of human breast cancers.

The study, called «Molecular Determinants of Drug - Specific Sensitivity for Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants in Non-Small Cell Lung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patients.

Osimertinib binds tightly to a protein, epidermal growth factor receptor (EGFR), which is overexpressed in many tumours.

Epidermal growth factor receptor (EGFR) signal transduction plays a major role in growth, proliferation and differentiation of mammalian cells.